|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2004-10-11
|
|
pubmed:abstractText |
Glioblastoma multiforme (GBM) remains the most devastating primary tumour in neuro-oncology. Targeting of the human epithelial receptor type 2 (HER2)-neu receptor by specific antibodies is a recent well-established therapy for breast tumours. Human epithelial receptor type 2/neu is a transmembrane tyrosine/kinase receptor that appears to be important for the regulation of cancer growth. Human epithelial receptor type 2/neu is not expressed in the adult central nervous system, but its expression increases with the degree of astrocytoma anaplasia. The specificity of HER2/neu for tumoral astrocytomas leads us to study in vitro treatment of GBM with anti-HER2/neu antibody. We used human GBM cell lines expressing HER2/neu (A172 express HER2/neu more than U251MG) or not (U87MG) and monoclonal humanised antibody against HER2/neu (Herceptin). Human epithelial receptor type 2/neu expression was measured by immunohistochemistry and flow cytometry. Direct antibody effect, complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity were evaluated by different cytometric assays. We have shown, for the first time, the ability of anti-HER2/neu antibodies to induce apoptosis and cellular-dependent cytotoxicity of HER2/neu-expressing GBM cell lines. The results decreased from A172 to U251 and were negative for U87MG, in accordance with the decreasing density of HER2/neu receptors.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-10327070,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-11147296,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-11331475,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-11599003,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-12060609,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-12168843,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-12460467,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-12532415,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-12595806,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-12902879,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-1374587,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-1689212,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-1973830,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-1977769,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-7507162,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-7826981,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-7903153,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-8102322,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-8227309,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-8294556,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-8622019,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-8826951,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-8875477,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-9266437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-9440030,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-9591843,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-9619719,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15328518-9811454
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
13
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1195-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15328518-Antibodies, Monoclonal,
pubmed-meshheading:15328518-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15328518-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:15328518-Antineoplastic Agents,
pubmed-meshheading:15328518-Cell Death,
pubmed-meshheading:15328518-Cell Line, Tumor,
pubmed-meshheading:15328518-Cytotoxicity, Immunologic,
pubmed-meshheading:15328518-Glioblastoma,
pubmed-meshheading:15328518-Humans,
pubmed-meshheading:15328518-Recombinant Proteins
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas.
|
|
pubmed:affiliation |
Department of Neurosurgery, University Medical School Hospital of Brest, BP 824, F29609 Brest Cedex, France. jfmineo@hotmail.com
|
|
pubmed:publicationType |
Journal Article
|
